NeoGenomics NEO Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $186.67M+11.1% | $190.17M+10.6% | $187.8M+11.9% | $181.33M+10.2% | $168.04M+7.5% | ||
| $105.81M+11.6% | $106.83M+12.8% | $107.35M+15.5% | $104.07M+13.1% | $94.79M+4.4% | ||
| $80.86M+10.4% | $83.34M+7.9% | $80.45M+7.4% | $77.26M+6.6% | $73.25M+11.9% | ||
| 43.3%-0.3pp | 43.8%-1.1pp | 42.8%-1.8pp | 42.6%-1.5pp | 43.6%+1.7pp | ||
| $9.53M-6.4% | $9.18M+15.2% | $8.69M+13.1% | $9.02M+14.4% | $10.18M+33.6% | ||
| $23.83M+5.1% | $23.44M+4.9% | $21.81M+6.8% | $24.08M+11.1% | $22.68M+12.2% | ||
| $65.74M-3.6% | $63.51M-0.2% | $69.87M+4.3% | $71.75M+13.3% | $68.21M+3.7% | ||
| $99.11M-1.9% | $96.76M+1.1% | $107.46M+11.8% | $124.89M+32.2% | $101.07M+5.2% | ||
| $99.11M-1.9% | $96.76M+1.1% | $107.46M+11.8% | $124.89M+32.2% | $101.07M+5.2% | ||
| -$18.24M+34.4% | -$13.41M+27.1% | -$27.01M-27.4% | -$47.63M-117% | -$27.83M+9.0% | ||
| -9.8%+6.8pp | -7.1%+3.6pp | -14.4%-1.8pp | -26.3%-12.9pp | -16.6%+3.0pp | ||
| $598K-63.0% | $599K-63.1% | $603K-63.3% | $933K-44.0% | $1.62M-4.0% | ||
| $1.27M-65.8% | $1.52M-64.8% | $1.56M-66.6% | $2.26M-50.7% | $3.72M-23.0% | ||
| -$12K-118% | $84K+119% | -$335K-206% | $482K+24,200% | $65K+125% | ||
| -$17.58M+31.5% | -$12.41M+23.1% | -$26.39M-47.8% | -$45.82M-141% | -$25.66M+7.3% | ||
| -$472K-277% | -$2.53M-214% | $740K+593% | -$724K-93.1% | $266K+143% | ||
| -$17.11M+34.0% | -$9.88M+35.5% | -$27.13M-53.3% | -$45.09M-142% | -$25.92M+4.2% | ||
| -9.2%+6.3pp | -5.2%+3.7pp | -14.4%-3.9pp | -24.9%-13.5pp | -15.4%+1.9pp | ||
| -$0.13+35.0% | -$0.07+41.7% | -$0.21-50.0% | -$0.35-133% | -$0.20+4.8% | ||
| 129.2M+1.4% | 128.1M+1.1% | 128.4M+1.2% | 127.9M+1.2% | 127.4M+1.0% | ||
| 129.2M+1.4% | 128.1M+1.1% | 128.4M+1.2% | 127.9M+1.2% | 127.4M+1.0% | ||
| -$0.13+35.0% | -$0.07+41.7% | -$0.21-50.0% | -$0.35-133% | -$0.2+4.8% | ||
| -$0.13+35.0% | -$0.07+41.7% | -$0.21-50.0% | -$0.35-133% | -$0.2+4.8% | ||
| —— | $6.94M— | $6.94M— | $6.94M— | $6.94M— | ||
| -$12K-118% | $84K+119% | -$335K-206% | $482K+24,200% | $65K+125% | ||
| -$18.24M+34.4% | -$13.41M+27.1% | -$27.01M-27.4% | -$47.63M-117% | -$27.83M+9.0% | ||
| -$1.83M+81.9% | $2.98M+1,500% | -$10.58M-229% | -$30.36M-692% | -$10.1M+17.9% | ||
| -$1.83M+81.9% | $2.98M+1,500% | -$10.58M-229% | -$30.36M-692% | -$10.1M+17.9% | ||
| -1%+5.0pp | 1.6%+1.7pp | -5.6%-3.7pp | -16.7%-14.4pp | -6%+1.9pp | ||
| -$18.24M+34.4% | -$13.41M+27.1% | -$27.01M-27.4% | -$47.63M-117% | -$27.83M+9.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is NeoGenomics's revenue?
- NeoGenomics (NEO) generated $746.0M in revenue over the trailing twelve months, up 10.9% year over year.
- Is NeoGenomics profitable?
- NeoGenomics is not currently profitable: it reported a net loss of $99.2M over the trailing twelve months, a -13.3% net margin.
- What are NeoGenomics's profit margins?
- Gross margin is 43.2% and operating margin is -14.2%, with a -13.3% net margin.
- What is NeoGenomics's earnings per share?
- NeoGenomics's diluted EPS over the trailing twelve months is $-0.76.
- Where does NeoGenomics's income statement data come from?
- Every line is extracted from NeoGenomics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
